itamin D is a steroid hormone precursor, which undergoes 2 hydroxylations, the first converting vitamin D to 25-hydroxyvitamin D (25(OH)D), which is an indicator of vitamin D status, and the second to the main active form, 1,25-dihydroxyvitamin D (1,25(OH)D). 1 Vitamin D deficiency may increase the risk of various autoimmune diseases, including rheumatoid arthritis (RA), and negatively affect RA activity. 2, 3 There are numerous studies linking vitamin D supplementation with improvement of muscle strength and body balance. 1, 4, 5 In addition, many researchers have shown the association between vitamin D deficiency and chronic pain, skeletal muscle weakness, mood disorders, and deterioration of cognitive function in the elderly. [6] [7] [8] [9] [10] [11] Among the disease-specific questionnaires evaluating the quality of life (QoL) in RA, the most widely used is Health Assessment Questionnaire (HAQ). 12 The world's most widely used generic scale is the Medical Outcome Study Short Form 36 (SF-36). The scale includes 36 questions grouped into 8 domains, which include: general health perception (GH), physical functioning (PF), reduction in performing roles resulting from physical problems (role physical [RP] ), reduction in performing roles resulting from emotional problems (role emotional [RE] ), social functioning (SF), physical pain (bodily pain [BP] ), vitality (VT), and mental health (MH). 13 The results can be presented in the form of a summary of the 2 main domains: physical (PCS) and mental (MCS). Vitamin D deficiency may be associated with worsening of physical and emotional well-being in patients with RA, so we aimed to establish the relationship between serum vitamin D levels and disease activity, physical activity (PA), and quality of life (QoL) in RA patients.
MATERIALS AND METHODS
Ninety-seven consecutive RA patients without vitamin D supplementation (86 women and 11 men aged 59.4 ± 12 years, with the mean disease duration 8.1 ± 9 years [0.1-40 years]) hospitalized in the Department of Rheumatology WIM CSK MON were included in the study. The control group consisted of 28 osteoarthritis (OA) patients (25 women and 3 men aged 56.2 ± 15 years). Seventy-six patients were hospitalized because of RA exacerbation or the need of treatment modification; the other 21 patients were newly diagnosed with RA during hospitalization. The patients signed the informed consent form. The study was approved by the local ethical committee. In 27 patients, testing was performed before RA treatment or during the first weeks of treatment. The data concerning disease duration, previous treatment, comorbidities, body mass index (BMI), the frequency of being outdoors, and the level of PA have been collected. Patients with RA completed the questionnaires: SF-36, Beck Depression Inventory (BDI), and HAQ, and determined the severity of pain and fatigue on visual analog scale (VAS). To calculate the grades of the SF-36 scale, we used the rules established for the Polish version of the scale by Tylka and Piotrowicz. 14 . The results were converted to percentages assuming that 100% means maximum welfare in a given subscale. Physical activity was quantified in a 5-grade scale from 0 (no exercises) to 4 (exercises at least 3 times a week for a minimum 1 hour). Disease activity was assessed according to the Disease Activity Score in 28 Joints (DAS28). Components of DAS28 are erythrocyte sedimentation rate, patient's global assessment (0-100), and swollen and tender joint count (both 0-28). High disease activity was defined as DAS > 5.1, moderate as 3.2 < DAS28 ≤ 5.1, low as 2.6 ≤ DAS28 ≤ 3.2, and remission as DAS28 < 2.6. In the statistical analysis, we used Statistica version 10.0 (StatSoft, Kraków, Poland). Results are reported as mean (SD) for continuous variables and n (%) for categorical variables. Student t test, Mann-Whitney U, and 1-way analysis of variance were used for the comparison of independent variables. Multiple regression analysis was used to assess relative importance of independent variables. Pearson or Spearman correlation was used for determining correlation. P < 0.05 was considered statistically significant.
RESULTS
Vitamin D deficiency was detected in 74 (76.3%) of 97 RA patients, among them 37 (38.1%) were deeply deficient (≤10 ng/ dL). Twenty-two OA patients (78.6%) were vitamin D deficient, and 10 (35.7%) deeply deficient-the difference between RA and OA groups was insignificant (P = 0.75). All examined patients had Ca, P, and PTH serum levels within normal limits; however, we found inverse correlation of 25(OH)D and PTH serum concentration (r = −0.3 P = 0.01).The patients with the highest serum levels of 25(OH)D (>30 ng/dL) had lower BMI than did the others (21.9 vs 27), but the difference was insignificant. All of SF-36 domains, HAQ, BDI, and DAS28 scores were slightly better in patients with sufficient vitamin D concentration, but only complete SF-36 was significantly different between groups and correlated positively with 25(OH)D concentration ( Table 1 ). The patients with moderate disease activity had lower vitamin D serum concentration than did patients with mild disease activity, and vitamin D levels were the lowest in patients with high disease activity. Taking into account only the patients with active disease (DAS28 ≥2.6), we have found a negative correlation between DAS28 and serum 25(OH)D3 (r = −0.26, P = 0.016). There was a positive correlation between the level of PA and vitamin D serum concentration. Glucocorticosteroid monotherapy was associated with only a trend to lower vitamin D level than in patients treated with disease-modifying drugs or in patients without RA treatment (P = 0.33).
In addition, we performed analysis after exclusion of the patients with RA treated less than 1 year (these patients are more likely to have stress associated with new diagnosis and less likely to achieve adequate response to treatment). Among 70 patients, 52 (74.3%) were vitamin D deficient, including 28 (40%) deeply deficient. Vitamin D deficient patients scored significantly worse than did the others in HAQ, BDI, and in SF-36 components (Table 2 ). In a univariate linear regression analysis, serum 25 (OH)D concentration showed significant influence on PCS, MCS, HAQ, and BDI scores (R 2 = 0.14, R 2 = 0.06, R 2 = 0.17, and R 2 = 0.07, respectively). Again there was a negative correlation between vitamin D concentration and DAS28 in patients with active arthritis (R 2 = 0.09, P < 0.05). In a multiple regression analysis including several variables considered important for QoL (age, disease duration, BMI, DAS28, VAS pain, and vitamin D concentration), the positive correlation between vitamin D level and overall SF-36 (including PF, RE, BP, and VT + MH domains) and negative correlation between vitamin D concentration and HAQ and BDI were found. After inclusion of PA as an independent variable, only the correlations with BP and MCS remained significant (Table 3) .
DISCUSSION
Several studies have confirmed that vitamin D deficiency is common in RA. 15 In our study, a majority of RA and OA patients were vitamin D deficient with no significant difference between examined groups. Recent surveys suggest that at least 80% of the Polish population shows vitamin D deficiency, so supposedly the latitude of our country is the primary determinant of the patients' low vitamin D status. 16 Many studies have demonstrated a negative correlation between serum 25(OH)D concentration and RA activity. [15] [16] [17] [18] [19] In a large cross-sectional study, Rossini et al 20 have found significantly lower 25(OH)D values in patients with active disease, responding poorly to treatment, and with the worst functional state. Haga et al 21 did not find any association between vitamin D concentration and DAS28, but a subpopulation with severe deficiency was characterized by a high percentage of patients with very high disease activity. In a placebocontrolled observational study with high-dose vitamin D supplementation, no benefit in disease activity or patient's global health was confirmed, but the number of participants was small. 22 In a recent study conducted by Higgins et al, 23 DAS28-erythrocyte sedimentation rate was calculated both with and without the patient's rating of their symptoms on the VAS scale. Only the correlation of vitamin D level with VAS was significant, suggesting that vitamin D deficiency simply increases pain perception. In our study, we did not find any correlation of vitamin D level with VAS pain and VAS fatigue, but we have found negative correlation between 25(OH)D and DAS28; however, it was significant only for the patients with active arthritis (DAS28 ≥2.6). Our results are comparable with a study in which 25(OH)D concentration was moderately and inversely associated with DAS28, and no significant associations between 25(OH)D and these variables in patients in remission were found. 24 It has been suggested that 25(OH)D serum concentrations may decrease in the acute-phase response, thereby explaining the low levels in patients with high disease activity. 25 Consequently, low vitamin D level may also be the result of disease activity. In another recent study, there was no correlation between seasonal serum 25(OH)D3 and disease activity in patients with RA; however, the majority of the patients were not vitamin D deficient. 26 The evidence that disease activity correlates with lower 25(OH)D serum levels needs further studies.
There are numerous studies examining the relationship of vitamin D deficiency with different aspects of QoL, but most of them are population-based studies. In the study evaluating the effect of vitamin D supplementation in outpatient veterans, the improvement of sleep, pain, general health, VT, and SF was observed. 8 In a British national community sample of people 65 years or older, 25(OH)D levels correlated negatively with the number of depressive symptoms. 27 Similar findings were reported in studies from Italy and the United States. 10, 11 In Iowa Women's Health Study, the researchers have found overall association between lower vitamin D daily intake and poorer QoL scores, including MH, RE, SF, VT, and GH. 9 However, adding PA to the multivariable model attenuated the overall association, and the significance remained only for MH and SF. In our study, in fact, the level of PA presented the essential difference between vitamin D-sufficient and -deficient patients. Inclusion of the level of PA as a variable has made most of the associations between vitamin D and QoL indices insignificant. Previous studies have indicated an association between physical components of QoL and PA, suggesting that those with lower levels of PA have also lower QoL. 28, 29 In addition, the association between PA and vitamin D was found in a number of studies. The Longitudinal Aging Study Amsterdam study has shown that PA was positively associated with 25(OH)D serum concentration in women. 30 Vitamin D deficiency was associated with worse physical performance. 31 The correlation between vitamin D deficiency and loss of muscle strength and muscle mass was found in a prospective study. 32 The patients with serum 25(OH)D of less than 25.0 nmol/L (10 ng/dL) had significantly lower physical performance than did those with serum 25(OH)D of 25 nmol/L or greater. 33 Vitamin D deficiency in elderly was associated with a worse coordination in women, a slower walking time in men, and with lower strength and aerobic capacity in both sexes. 34 The changes in 25(OH)D level correlated positively with the growth of muscle mass and strength in older adults, even in absence of regular physical exercises. 35 The most relevant changes in physical abilities were observed at 25(OH)D levels between 10 and 30 ng/dL, with the effect threshold of around 40 to 50 ng/dL, above which further improvement of neuromuscular performance was not observed. 36 These studies indicate that PA may lie on the causal pathway between vitamin D status and QoL, so considering PA as an independent factor may be inappropriate.
Our study has several limitations. First, we decided to include in the study only the patients without vitamin D supplementation. Vitamin D supplementation with 1(OH)D (alfacalcidol) was quite popular in Poland, and many RA patients were not sure what kind of substance they had used as vitamin D, so we were unable to exactly evaluate vitamin D status in patients taking different vitamin D metabolites. Second, inclusion of consecutive RA inpatients resulted in presence of a substantial group of early RA patients, which are more likely to have higher disease activity and worse outcomes in most QoL scales. As a result, the most important analyses were performed in a group of 70 patients. The other weakness of our study is that the serum 25(OH)D was measured only once. Furthermore, we did not assess some factors that may alter the association between vitamin D status and MH, such as education, marital and economic status, smoking, and alcohol consumption. Despite this, and probably because of the high prevalence of vitamin deficiency in examined group, we managed to find significant associations between vitamin D status and mental and physical aspects of QoL, as well as with disease activity.
CONCLUSIONS
Vitamin D deficiency is highly prevalent in RA patients and is related with worse QoL, lower level of PA, and a higher disease activity, the last only in patients with active arthritis. 
